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Collagen Synthesis Is Suppressed in Dermal
Fibroblasts by the Human Antimicrobial Peptide
LL-37
Hyun Jeong Park1,6, Dae Ho Cho2,6, Hee Jung Kim1, Jun Young Lee1, Baik Kee Cho1, Sa Ik Bang3,
Sang Yong Song4, Kenshi Yamasaki5, Anna Di Nardo5 and Richard L. Gallo5
LL-37 is a human cathelicidin antimicrobial peptide that is released in the skin after injury and acts to defend
against infection and modulate the local cellular immune response. We observed in human dermal keloids that
fibrosis was inversely related to the expression of cathelicidin and sought to determine how LL-37 influenced
expression of types I and III collagen genes in dermal fibroblasts. At nano-molar concentrations, LL-37 inhibited
baseline and transforming growth factor-b-induced collagen expression. At these concentrations, LL-37 also
induced phosphorylation of extracellular signal-regulated kinase (ERK) within 30 minutes. Activation of ERK, and
the activation of a G-protein-dependent pathway, was essential for inhibition of collagen expression as pertussis
toxin or an inhibitor of ERK blocked the inhibitory effects of LL-37. c-Jun N-terminal kinase and p38 mitogen-
activated protein kinase inhibitors did not alter the effects of cathelicidin. Silencing of the Ets-1 reversed
inhibitory effects of LL-37. Taken together, these findings show that LL-37 can directly act on dermal fibroblasts
and may have antifibrotic action during the wound repair process.
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INTRODUCTION
Antimicrobial peptides are small cationic polypeptides
originally discovered for their antimicrobial activity, but
recently shown to have many additional functions in immune
function (Elsbach, 2003). Cathelicidins have an N-terminal
signal peptide, a highly conserved cathelin domain, and
variable cationic peptide at the C terminus (Zanetti et al.,
1995). The human cathelicidin peptide LL-37 has broad
antibacterial activity in vitro and possesses a variety of other
biological activities including promoting angiogenesis,
wound repair, and chemoattraction of neutrophils, mono-
cytes, and T cells (Gallo et al., 1994; Nizet et al., 2001;
Koczulla et al., 2003). The synthesis and deposition of
cathelicidins during defense against infection or injury occurs
due to its combined production by epithelial cells, neutro-
phils, mast cells, and other specialized elements of specific to
the injured tissue (Di Nardo et al., 2003). Once released,
cathelicidin is important in both innate immunity and
acquired immunity. In the form of LL-37, this peptide can
induce inflammation, epithelial proliferation, and migration,
and may have been involved in the response to injury (Gallo
et al., 1994; Koczulla et al., 2003). Despite these observa-
tions of the significance of LL-37 in the wound repair process,
little work has been performed to evaluate the potential
influence of this molecule on the extracellular matrix (ECM),
in particular collagen synthesis, a critical element of the
fibrotic response.
Collagen is the most abundant connective tissue in
humans, and collagen fibers provide the tensile strength that
allows organs such as the skin to form organized structures.
The type I collagen is the most widely distributed and also
forms the bulk of skin collagen, accounting for over 80% of
dermis. Type III collagen is the second most abundant
collagen found in the skin. The triple-helical structure gives
collagen many of its unique properties and is essential for
normal fibrogenesis. The metabolism of collagen and its
regulation are significant to many important diseases that are
characterized by excessive accumulation or loss of collagen
(Meneghin and Hogaboam, 2007; Wynn, 2007). Excessive
accumulation of collagen is known in disorders such as
scleroderma, keloids, hypertrophic scars, and also in tumor
growth. Outside the skin, pulmonary fibrosis, systemic
sclerosis, liver cirrhosis, cardiovascular diseases, and pro-
gressive kidney disease are leading causes of morbidity and
mortality.
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In this study we investigated the expression of cathelicidin
in a skin disease associated with fibrosis, keloids, and studied
the effect of LL-37 on collagen expression in human
dermal fibroblasts (HDF). Our results show that cathelicidin
produced during the response to injury may influence the
dermal fibrotic response essential for repair and tissue
remodeling.
RESULTS
Cathelicidin expression is decreased in keloids
Keloid is a disorder characterized by uncontrolled prolifera-
tion of fibrous tissue following injury, and collagen synthesis
is markedly increased in keloid lesions. We investigated
cathelicidin expression in keloid tissue compared with
normal skin by immunostaining with a specific antibody to
LL-37 and found that cathelicidin protein expression was
lower in the overlying epidermis in keloid patients’ skin than
in normal controls (Figure 1). This result suggested that
cathelicidin expression was downregulated in keloid patients’
epidermis and that the surrounding cells in this tissue were
exposed to a lower level of cathelicidin. The significance of
this observation on the production of collagen by the
underlying dermal fibroblasts was therefore of interest.
Effect of LL-37 on collagen production in human dermal
fibroblasts
To measure the effect of LL-37 on collagen expression in
HDF, cells were treated with various doses of LL-37 for 24
hours and COL1A1 mRNA expression and cell viability were
measured. A trend for decreased expression of COL1A1 was
seen at the low dose range and increased expression at higher
doses that approached the threshold for cell toxicity
(Figure 2). Next, experiments were performed with a fixed
concentration of LL-37 (40 nM) and the expression
of COL1A1, COL1A2, and COL3A1 mRNA were each
measured as was collagen protein production as measured
by the Sircol collagen assay. COL1A1, COL1A2, and
COL3A1 mRNA expression was significantly decreased by
LL-37 (Figure 3a). Total soluble collagen was also decreased
(Figure 3b) and the degree of inhibition was similar to that
seen following exposure to IFN-g, previously established as
an inhibitor of fibroblast collagen synthesis.
To further evaluate the effects of LL-37 on collagen
synthesis, its action on cells stimulated with a pro-fibrotic
response was evaluated. Transforming growth factor (TGF)-b
is an important participant in the process of fibrosis and
pathogenesis of fibrotic disorders by stimulating collagen
synthesis in fibroblasts. As expected, treatment of HDF with
TGF-b induced collagen gene and protein expression. The
presence of low concentrations of LL-37 suppressed TGF-b
induced COL1A1, COL1A2, and COL3A1 mRNA expressions
and soluble total collagen levels (Figure 4a and b). LL-37 also
inhibited TGF-b induction of Smad2 and Smad3 phosphor-
ylation (Figure 4c). To examine the effect on collagen gene
transcription, transient cell transfections were performed with
the collagen promoter/gene reporter constructs 2,019
COL1A1/Luc. LL-37 had slightly inhibitory effects on the
constructs containing 2,019 bp of COL1A1 promoter
sequences. Also, LL-37 decreased TGF-b-stimulated COL1A1
promoter activity (Figure S1).
Effect of pertussis toxin on collagen gene expression induced by
LL-37
LL-37 is known to act in part through G-protein-coupled
receptors (GPCR) to initiate cellular responses including
cytokine release and cell migration. To study whether a
GPCR is involved in the mediating LL-37 effects on collagen
synthesis in HDF, the cells were pretreated with 200 ngml1
Pertussis toxin (PTX) before stimulation with 40 nM of LL-37
mRNA levels of COL1A1, COL1A2, and COL3A1 were then
analyzed by real-time reverse transcriptase (RT)-PCR. PTX
pretreatment reversed inhibitory effects of LL-37 on the
production of collagen (Figure 5a and b), showing that GPCR
is required for activities of LL-37 on fibroblast.
Effect of mitogen-activated protein kinase inhibitor on collagen
expression
The mitogen-activated protein kinases (MAPKs) control a
wide variety of cellular events including complex cellular
programs such as differentiation, proliferation, apoptosis, and
processes involved in immune responses. The observation
that LL-37 treatment leads to the inhibition of collagen
expression prompted us to examine whether MAPK-signaling
pathways participate in the regulation of collagen expression.
Initial studies were performed to determine the effect of the
MAPK inhibitors on mRNA transcription of collagen. HDF
were treated with the inhibitors of extracellular signal-
regulated kinase (ERK) (PD98059), p38 MAPK (SB203580),
and c-Jun N-terminal kinase (JNK) (SP600125) before the
addition of 40 nM LL-37. Only PD98059 could reverse the
inhibition of LL-37-induced collagen gene and protein
production, suggesting that ERK was involved in the signaling
pathway in HDF (Figure 6a and b).
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Figure 1. Cathelicidin expression is decreased in the skin of keloid patients.
(a) The intensity of immunostaining with an antibody specific to LL-37 was
visually scored on a scale from 0 to 3, with 0 indicating no staining and 3 the
most intense staining. *Po0.05 versus normal. (b) Immunostaining for
cathelicidin in paraffin-embedded skin sections from normal subjects (upper
panel) and patients with keloid. Scale bar: 100 mm.
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To directly evaluate the activation of ERK, HDF were
treated with LL-37, and the phosphorylation of ERK
was analyzed by western blotting using anti-ERK antibodies.
LL-37 induced a transient phosphorylation of ERK, and
the maximal activation of ERK by LL-37 was observed
after 30 minutes (Figure 6c). The ERK inhibitor PD98059 at
10 mM inhibited LL-37-induced phosphorylation of ERK
(Figure 6d). Combined, these results indicate that LL-37
downregulates collagen expression by the activation
of the ERK pathway, and that this event is dependent on
GPCR.
Ets-1 involves in the regulation of collagen expression by LL-37
Recently, the Ets transcription factors have been known to
associated with regulation of ECM genes, including type I
collagen (Czuwara-Ladykowska et al., 2002; Sherriff-Tadano
et al., 2006). We observed Ets-1 involvement in collagen
gene expression by LL-37, Ets-1 expression significantly
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Figure 2. Effects of LL-37 on the expression of COL1A1 mRNA in human dermal fibroblasts. (a, b) HDF cells were treated with indicated concentration
of LL-37. After 24 hours, total RNA was extracted, and real-time RT-PCR was performed. Bars indicate mean±SD of three independent experiments performed,
each with triplicate samples. (c) Cells were treated with indicated concentration of LL-37 for 24 hours, after which cell viability was measured using an
Alama-Blue assay.
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Figure 3. Effects of LL-37 on the mRNA expression and production of COL1A1, COL1A2, and COL3A1 in human dermal fibroblasts. (a) HDF cells were
harvested after LL-37 (40 nM) and IFN-g (1,000Uml1) treatment for 24 h. Total RNA was extracted, and cDNA was synthesized for real-time RT-PCR. Bars
indicate mean±SD of three independent experiments performed, each with triplicate samples. (b) Cells were cultured in serum-free medium. Protein was
determined in supernatants after 48 hours of culture. Total collagen was detected by sircol assay, each performed in triplicate. Data are mean±SD. *Po0.05
versus control.
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Figure 4. LL-37 inhibited collagen gene expression and production induced by TGF-b. (a) HDF cells were pretreated with 10 ngml1 of TGF-b for 2 hours,
before addition of 40 nM of LL-37. After 24 hours, total RNA was extracted, and real-time RT-PCR was performed. Bars indicate mean±SD of three independent
experiments performed, each with triplicate samples. (b) Protein was determined in supernatants after 48 hours of culture. Total collagen was detected by sircol
assay, each performed in triplicate. Data are mean±SD. *Po0.05 versus control, yPo0.05 versus TGF-b-treated group. (c) LL-37 inhibited TGF-b-induced
phosphorylation of Smad. HDF cells were pretreated with TGF-b (10 ngml1) for 2 hours, and then challenged with 40 nM LL-37. After 24 hours, whole cell
lysates (30 mg per lane) were probed with antibodies against Smad2/3, phospho-Smad2, phospho-Smad3 in Western blots.
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increased in HDF after 24 hours of LL-37 treatment
(Figure 7a). Treatment of fibroblasts with Ets-1 small
interfering RNA (siRNA) for 24 hours resulted in reduction
of Ets-1 mRNA levels by 70% (Figure 7b). In addition,
COL1A1 and COL1A2 mRNA levels were examined in HDF
treated with Ets-1 siRNA. Silencing of the Ets-1 reversed
inhibitory effects of LL-37 on the expression of both COL1A1
and COL1A2 mRNA (Figure 7c). Western blot analysis
revealed that type I collagen expression was also reversed
by Ets-1 siRNA (Figure 7d). These data suggest that Ets-1
could be involved in negative regulation of type I collagen
expression by LL-37.
Effect of LL-37 on collagen production in human keloid
fibroblasts
We also examined whether LL-37 could regulate collagen gene
expression in primary human fibroblasts derived from keloids.
As shown in Figure 8a, COL1A1, COL1A2, and COL3A1
mRNA expression was decreased by LL-37 in keloid fibroblasts.
Total soluble collagen was also decreased (Figure 8b).
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Figure 5. Effects of pertussis toxin (PTX) on collagen gene expression and production inhibited by LL-37. HDF cells were pretreated with 200 ngml1 of
pertussis toxin for 2 hours, before addition of 40 nM LL-37. (a) Total RNA was extracted at 24 hours following LL-37 treatment, and real-time RT-PCR was
performed. Bars indicate mean±SD of three independent experiments performed, each with triplicate samples. (b) Protein was determined in supernatants after
48 hours of culture. Total collagen was detected by sircol assay, each performed in triplicate. Data are mean±SD. *Po0.05 versus control, yPo0.05 versus LL-
37-treated group.
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20mM of JNK inhibitor SP600125 for 1 hours, and then challenged with 40 nM LL-37. After incubations, collagen gene expression was detected by real-time
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blot as described in section ‘‘Materials and Methods.’’ (d) Cells were incubated with PD98059 (10 mM) for 2 hours before addition of LL-37 (40 nM). After 30
minutes cells were harvested, phosphorylation of ERK was analyzed by Western blot.
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DISCUSSION
In the present study, we showed the regulatory effect of LL-37
on production of collagen in HDF. Our results further show
that LL-37 inhibits HDF collagen production through GPCR-,
ERK-, and Ets-1-dependent pathways. To our knowledge, this
is the first report that LL-37 has inhibitory effects on collagen
production in fibroblasts. We investigated types I and III
collagen because type I collagen accounts for around 80%
and type III for most of the other collagens of adult human
dermis. LL-37 inhibits COL1A1, COL1A2, and COL3A1
mRNA expression levels similar to that induced by IFN-g,
which is used as antifibrotic treatments in keloid patients.
Conversely, TGF-b is crucial in the pathogenesis of fibrosis. In
our study, LL-37 also inhibited TGF-b-induced collagen gene
expression and soluble collagen production.
TGF-b induces fibrosis through smad or non-smad path-
ways (Varga and Abraham, 2007). Eight different members of
the Smads family have been identified in mammals, and
Control ControlLL-37
Ets-1
β-actin
Ets-1
β-actin
700
600
500
400
300
200
100
0
R
el
at
ive
 m
R
N
A 
le
ve
l
(%
 of
 co
ntr
ol)
R
el
at
ive
 m
R
N
A 
le
ve
l
(%
 of
 co
ntr
ol)
COL1A1
siEts-1
120
100
80
60
40
20
0
Control
siEts-1
siRNA control
Control
siEts-1
siRNA control
R
at
io
 (ta
rge
/β-
a
ct
in
)
2.0
1.5
1.0
0.5
0.0
LL-37 − + − + − +
R
at
io
 (ta
rge
/β-
a
ct
in
)
2.0
1.5
1.0
0.5
0.0
LL-37 − + − + − +
COL1A2
siRNA control
− + − +
siEts-1
LL-37
Type I
collagen
Tubulin
210
180
150
120
90
60
30
0
Le
ve
l o
f t
yp
e 
I c
ol
la
ge
n
(%
 of
 co
ntr
ol)
Figure 7. Effects of Ets-1 on collagen expression inhibited by LL-37. (a) HDF cells were harvested after LL-37 (40 nM) treatment for 24 h. Total RNA was
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for RT–PCR. The histogram shows Ets-1 mRNA level relative to b-actin by densitometry. Cells were transfected with control siRNA or siEts-1. Cells were
harvested after LL-37 treatment for 24 or 48 h. (c) After 24 hours, collagen gene expression was detected by real-time RT-PCR. Bars indicate mean±SD of three
independent experiments, each with triplicate samples. (d) After 48 hours cells were harvested, type I collagen production was analyzed by Western blot. The
band intensities were quantitated.
www.jidonline.org 847
HJ Park et al.
Collagen Synthesis Suppressed by LL-37
Smad2 and Smad3 are specific mediators in fibrogenesis. LL-
37 inhibited TGF-b induction of Smad2 and Smad3
phosphorylation. Non-smad pathways are also important in
the regulation of fibrosis. Members of the MAPK family; ERK,
p38 MAPK, and JNK, are frequently involved in TGF-b-
induced fibrosis. We showed that LL-37 regulates collagen
gene expression and soluble collagen production in HDF
through ERK pathway.
LL-37 is known to act in part on mammalian cells through
binding to formyl peptide receptor-like1, which is one of
GPCR. Here we found that the inhibitory effects of LL-37
were reversed after pretreatment of PTX, an inhibitor of
GPCR. Therefore, as in other specific cell activation events,
the antifibrotic effects of LL-37 on HDF are also regulated
through GPCR.
Recent evidence suggests that Ets factor is associated with
regulation of ECM genes (Czuwara-Ladykowska et al., 2002;
Mizui et al., 2006; Sherriff-Tadano et al., 2006). Mizui et al.
demonstrated that overexpression of Ets-1 prevented the
TGF-b induction of type I collagen production in cultured
mesangial cells. Knockdown of Ets-1 in glomeruli resulted in
severe ECM deposition and diseased glomeruli (Mizui et al.,
2006). Furthermore, Ets-1 strongly suppressed TGF-b induc-
tion of type I collagen and other matrix-related genes
(Czuwara-Ladykowska et al., 2002). In the present study,
treatment with Ets-1 siRNA blocked the downregulation of
type I collagen expression by LL-37. Thus, these results have
suggested that Ets-1 mediates the regulation of type I collagen
expression inhibited by LL-37.
Bo¨hm et al. showed that one of antimicrobial peptide,
a-MSH, has antifibrotic effects in HDF, although a-MSH only
suppresses collagen protein levels and not mRNA levels
(Bo¨hm and Luger, 2004; Bo¨hm et al., 2004). There are also a
few reports about profibrotic effects of a-defensin, which is
expressed in human neutrophils, and is also referred to as
human neutrophil peptide (Chavakis et al., 2004; Li et al.,
2006). Oono et al. showed that synthetic HNP-1 enhanced
the expression of pro-a1(I) collagen in cultured HDF (Oono
et al., 2002). Yoshioka et al. also demonstrated that a-
defensin enhances collagen expression in human lung
fibroblasts (Yoshioka et al., 2007), but there has been no
report about LL-37.
Fibrotic skin diseases are clinically characterized by
thickening of skin due to accumulation of ECM, mainly
collagen. Keloid is manifested by localized lesions of
considerable cosmetic concern and is associated with
significant morbidity in terms of inflammation, infections,
pruritus, and pigmentary alterations (Urioste et al., 1999). The
primary cause of keloids is currently unknown, but their
development is clearly associated with injury to the skin and
can be predicted by genetic predisposition of susceptible
individuals (Urioste et al., 1999). We observed that LL-37
expression is lower in keloid patients compared with normal
control. LL-37 expression is also decreased in skin disease
such as atopic dermatitis, which contributes to increased
infection in atopic dermatitis patients (Ong et al., 2002).
Although LL-37 expression levels have not been known in
fibrotic diseases such as keloids, our results could suggest that
LL-37 is downregulated in keloid patients, resulting in
diminished antifibrotic signaling and excessive collagen
production.
In conclusion, we demonstrate that LL-37 inhibits collagen
expression in fibroblasts and is associated and dependent on
phosphorylation of ERK. These findings may provide insight
into immune interactions between LL-37 and the mechanism
of fibrosis. Because LL-37 is involved in multiple functions of
immune regulation, the ability of LL-37 to inhibit the
production of collagen by fibroblasts provides an additional
mechanism for the involvement of LL-37 in innate and
adaptive immunity and its role in the pathogenesis of skin
disorders.
MATERIALS AND METHODS
Cell culture
HDF from neonatal foreskin were obtained from the American Type
Culture Collection (CRL-2097, Manassas, VA). The cells were
cultured in Dulbecco’s modified Eagle’s medium (Gibco-BRL,
Gaithersburg, MD) supplemented with antibiotics (100Uml1
penicillin G and 100 mgml1 streptomycin) and 10% heat-inacti-
vated fetal bovine serum (Gibco-BRL). This cell line was used for
experiments while in their log phase of growth. The cells were
incubated in a humidified atmosphere containing 5% CO2 at 37 1C
and were used at passages 4–11. Keloid fibroblasts were harvested
from two volunteer patients. The ethical committee of the Catholic
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Figure 8. LL-37 inhibited collagen gene expression and production induced by TGF-b in primary keloid fibroblasts. (a) Keloid fibroblast cells were pretreated
with or without TGF-b (10 ngml1) for 2 hours and incubated in the presence or absence of LL-37 (40 nM) or IFN-g (1,000Uml1) for 24 h. Total RNA was
extracted, and cDNA was synthesized for quantitative real-time RT-PCR. Bars indicate mean±SD of three independent experiments performed, each with
triplicate samples. (b) Cells were cultured in serum-free medium. Protein was determined in supernatants after 48 hours of culture. Total collagen was detected
by sircol assay, each performed in triplicate. Data are mean±SD. *Po0.05 versus control, yPo0.05 versus LL-37-treated group.
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University of Korea approved the study and all patients provided
written, informed consent. The study was designed and conducted in
accordance with the Declaration of Helsinki. Keloid tissue was
washed repeatedly with phosphate-buffered saline (PBS), and
minced into 0.5–1mm pieces. Then the dermal tissue pieces were
incubated in a 0.25% collagenase type I solution (Sigma, St Louis,
MO) at 37 1C for 4 h. Keloid fibroblasts were maintained in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum and 1% antibiotic–antimycotic (100Uml1 penicillin G,
100mgml1 streptomycin, and 0.25mgml1 amphotericin B) (Gib-
co-BRL) at 37 1C in a humidified (5% CO2) incubator. Fibroblast
cells were subcultured at 80–90% confluence using PBS containing
0.025% trypsin-EDTA. Only cells of passages 3–7 were analyzed in
this study.
Cell viability assay
Viability of cells was determined indirectly using Alama-BlueTM
(Serotec, UK). Briefly, after the exposure of cells to LL-37 (Phoenix
Pharmaceuticals, Belmont, CA), each well (3 104 cells per well)
was added with 50mg Alama-Blue solution followed by incubation
for 3 hours in the incubator at 37 1C. Finally, absorbance was
measured at a wavelength of 570 nm, and background absorbance at
600 nm was subtracted.
Cell treatment with inhibitors
Cells were seeded at a density of 5 105 cells per 100-mm dish.
After 48 hours, the cells were washed with a serum-free medium and
then placed in a media without fetal bovine serum for at least 16
hours before experiments. In some experiments, cells were
pretreated with 10mM SB203580 (Sigma), a p38 MAPK inhibitor;
10 mM PD98059 (Sigma), an ERK inhibitor; 20 mM SP600125, a JNK
inhibitor; or 200 ngml1 PTX (Sigma). We added human LL-37
(40 nM), IFN-g (1,000Uml1), or TGF-b (10 ngml1) to the cells for
24 h.
RT–PCR
After treatment, total RNA was extracted using the Trizol reagent
(Invitrogen, Carlsbad, CA). Two micrograms of total RNA was used
for first strand cDNA synthesis using moloney murine leukemia virus
reverse transcriptase (Promega, Madison, WI), according to the
manufacturer’s instructions. Ets-1 primers were: forward, 50-ACGAT
AGTTGTGATCGCCTCA-30; reverse, 50-CCATAGCTGGATTGGTC
CACT-30. The PCR amplification consisted of 32 cycles of 94 1C
for 30 seconds; 58 1C for 30 seconds; and 72 1C for 1 minute. Human
b-actin primers were: forward, 50-TCACCCACACTGTGCCCATC
TACG-30; reverse, 50-CAGCGGAACCGCTCATTGCCAATG-30. The
PCR amplification consisted of 30 cycles of 94 1C for 30 seconds;
56 1C for 30 seconds; and 72 1C for 1 minute. 2 PCR Master mix
Solution (i-Taq, iNtRON Biotechnology, Korea) was used to perform
RT–PCR reactions. The PCR products subjected to electrophoresis on
1.5% agarose gel were visualized with ethidium bromide.
Quantitative real-time PCR
Total RNA and the cDNAs were generated as described above. Real-
time PCR was performed with a Rotor gene 3,000 instrument
(Corbett Life Science, Sidney, AU) using SYBR Premix Ex Taq
(Takara, Shiga, Japan). Reaction mixtures were incubated for 40
cycles at 95 1C for 15 seconds; 58 1C for 45 seconds; and 72 1C for 20
seconds. The relative amounts of gene expression were calculated by
using the expression of b-actin as an internal standard. Primers used
for PCR reactions are shown in Table 1.
RNAi and transfection
HDF was transfected with either 40 pmol control siRNA (SantaCruz,
CA) or Ets-1 siRNA (SantaCruz) using the Nucleofector apparatus
(AMAXA, Ko¨ln, Germany), as described by the manufacturer. After
16 hours incubation in serum-free Dulbecco’s modified Eagle’s
medium, cells were incubated in the presence or absence of 40 nM
LL-37. Twenty-four hours later, cells were harvested to total RNAs to
examine the effect on collagen expression. After 48 hours, cell
extracts were subjected to western blot analysis with anti-type I
collagen (Southern Biotechnology, Birmingham, AL) and g-tubulin
(SantaCruz) antibodies.
Measurement of total collagens
Sircol soluble collagen assay (Biocolor Ltd., Newtownabbey, UK)
was used to quantify total soluble collagens. Briefly, collected
supernatant was centrifuged at 1,500 r.p.m. for 5 minutes to drop
ECM, followed by mixing 100 ml supernatant with 1ml of Sircol dye
for 30 minutes and centrifuging at 10,000 r.p.m. for 10 minutes to
drop formed collagen–dye complex. After removing suspension, the
pellets were dissolved in 1ml Sircol alkali reagent and vortexed.
Relative absorbance was measured at 540 nm.
Western blot analysis
Whole cell lysates were prepared by extracting proteins using a
buffer containing 50mM Tris-HCl (pH 7.5), 1mM EDTA, 1mM EGTA,
150mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1mM Na3VO4,
1mgml1 leupeptin, and 1mM freshly added phenylmethylsulfornyl
fluoride. The protein concentration was measured using the Bio-Rad
Protein Assay Kit (Bio-Rad Laboratories). Proteins of 30 mg of whole
cell lysate were directly separated by 10% SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes. Mem-
branes were blocked for 1 hour in PBS containing 0.1% (v/v) Tween
20 and 5% (w/v) non-fat milk proteins. Blocked membranes were
then incubated with primary antibodies (anti-phospho-Smad2,
Table 1. Primer sequences used in this study
Name Forward sequence Reverse sequence
COL1A1 50-GGGCAAGACAGTGATTGAATA-30 50-ACGTCGAAGCCGAATTCCT-30
COL1A2 50-TCTGGATGGATTGAAGGGACA-30 50-CCAACACGTCCTCTCTCACC-30
COL3A1 50-AGGTCCTGCGGGTAACACT-30 50-ACTTTCACCCTTGACACCCTG-30
b-actin 50-TCACCCACACTGTGCCCATCTACG-30 50-CAGCGGAACCGCTCATTGCCAATG-30
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anti-phospho-Smad3, anti-Smad2/3, anti-phospho-ERK, or anti-ERK
rabbit polyclonal antibodies at the final concentration of 1:1000,
Cell Signaling, Beverly, MA) overnight at 4 1C, washed three times
(15 minutes each) with PBS containing 0.1% Tween 20, and
incubated with a horseradish peroxidase-conjugated anti-goat, or
anti-rabbit secondary antibody (1:2,000) for 1 hour at room
temperature. The bands were visualized by an enhanced chemilu-
minescence detection system (Amersham Biosciences, Piscataway,
NJ). The band intensities were quantified using the Bio-Rad imaging
system, and the quantity of the phosphorylated proteins was
expressed as ratio of the phosphorylated over total protein in each
case.
Immunohistochemistry
Five-micrometer-thick formalin-fixed, paraffin embedded biopsy
sections were obtained from five keloid patient samples and from
six control specimens. The study was approved by the ethical
committee of the Catholic University of Korea and all patients filed
an informed consent. We detected human LL-37 expression in tissue
sections using anti-cathelicidin LL-37 primary antibody or pre-
immune serum as described previously (Dorschner et al., 2001). The
paraffin-embedded tissue sections were deparaffinized in xylene and
rehydrated in a graded series of alcohol. The antibody was diluted in
PBS plus 0.1% Triton X-100 at a ratio of 1:300, and was incubated in
a wet chamber overnight at 4 1C. The antigen was detected using the
streptavidin–biotin–peroxidase detection system (Cap-plus Detection
Kit, Zymed Laboratories Inc., San Francisco, CA) with 3-amino-9-
ethylcarbazole as chromogen and Mayer haematoxylin as the
counterstain. Normal rabbit IgG (Zymed Laboratories Inc.) was used
for negative control. The degree of expression was graded as follows:
3 for strongly positive, 2 for moderately positive, 1 for weakly
positive, and 0 for negative.
Statistical analysis
The statistical significance was estimated using Student’s t-test. Mean
differences were considered to be significant when Po0.05. The
results are shown as the mean±SD.
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